The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 29 results:
Author Title Type [ Year(Asc)]
Filters: Author is Imprialos, Konstantinos P  [Clear All Filters]
2019
Stavropoulos, K., Imprialos K. P., Faselis C., Karagiannis A., & Papademetriou V. (2019).  Determinants of pulse wave velocity index and potential implementations.. J Clin Hypertens (Greenwich).
Stavropoulos, K., Imprialos K. P., Doumas M., Karagiannis A., & Papademetriou V. (2019).  Insomnia and hypertension: A misty landscape.. J Clin Hypertens (Greenwich). 21(6), 835-837.
Koutsampasopoulos, K., Vogiatzis I., Ziakas A., Papadopoulos C., Imprialos K. P., Stavropoulos K., et al. (2019).  Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure.. J Sex Med.
2018
Imprialos, K. P., Stavropoulos K., & Doumas M. (2018).  Antihypertensive drug treatment: the real-life challenge.. J Clin Hypertens (Greenwich). 20(1), 115-117.
Stavropoulos, K., Imprialos K. P., Doumas M., & Athyros V. G. (2018).  Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?. J Clin Hypertens (Greenwich). 20(2), 255-257.
Athyros, V. G., Doumas M., Imprialos K. P., Stavropoulos K., Georgianou E., Katsimardou A., et al. (2018).  Diabetes and lipid metabolism.. Hormones (Athens). 17(1), 61-67.
Doumas, M., Imprialos K. P., & Stavropoulos K. (2018).  Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.. N Engl J Med. 378(10), 967.
Doumas, M., Imprialos K. P., Stavropoulos K., & Athyros V. G. (2018).  Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. J Clin Hypertens (Greenwich). 20(3), 469-471.
Imprialos, K. P., Stavropoulos K., Doumas M., Skalkou A., Zografou I., & Athyros V. G. (2018).  The potential role of statins in treating liver disease.. Expert Rev Gastroenterol Hepatol. 12(4), 331-339.
Stavropoulos, K., Imprialos K. P., Katsiki N., Petidis K., Kamparoudis A., Petras P., et al. (2018).  Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich). 20(5), 942-948.
Stavropoulos, K., Imprialos K. P., Athyros V. G., & Doumas M. (2018).  Renal resistive index for renovascular hypertension: In the quest of the Holy Grail.. J Clin Hypertens (Greenwich). 20(3), 589-591.
Doumas, M., Stavropoulos K., Imprialos K. P., Athyros V. G., & Karagiannis A. (2018).  Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. J Clin Hypertens (Greenwich). 20(4), 634-636.
Stavropoulos, K., Imprialos K. P., & Doumas M. (2018).  Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.. J Clin Hypertens (Greenwich). 20(1), 65-68.
Imprialos, K. P., Stavropoulos K., Stavropoulos N., Patoulias D., Petidis K., Grassos C., et al. (2018).  Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs.. Cardiovasc Hematol Disord Drug Targets. 18(2), 104-113.
Stavropoulos, K., Imprialos K. P., Stavropoulos N., Bouloukou S., Kerpiniotis G., Dimitriadis K., et al. (2018).  Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.. Cardiovasc Hematol Disord Drug Targets. 18(2), 120-126.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2018).  Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs.. Cardiovasc Hematol Disord Drug Targets. 18(2), 83-85.
Stavropoulos, K., Imprialos K. P., Doumas M., Athyros V. G., & Karagiannis A. (2018).  Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. J Hypertens. 36(3), 701.
2017
Stavropoulos, K., Imprialos K. P., & Doumas M. (2017).  Abnormal blood pressure dipping in diabetic kidney disease: A black-race nightmare?. J Clin Hypertens (Greenwich). 19(12), 1336-1338.
Doumas, M., Stavropoulos K. V., Boutari C., Imprialos K. P., & Karagiannis A. (2017).  Blood pressure and cardiovascular outcomes: a closer look.. Lancet. 389(10076), 1295-1296.
Imprialos, K. P., Stavropoulos K., Doumas M., Karagiannis A., & Athyros V. G. (2017).  The effect of SGLT2 inhibitors on cardiovascular events and renal function.. Expert Rev Clin Pharmacol. 10(11), 1251-1261.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2017).  Liraglutide and Renal Outcomes in Type 2 Diabetes.. N Engl J Med. 377(22), 2196.
Imprialos, K. P., Stavropoulos K., & Doumas M. (2017).  Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.. N Engl J Med. 377(25), 2502.
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., & Karagiannis A. I. (2017).  Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. J Neurol Neurosurg Psychiatry. 88(3), 249-253.
Stavropoulos, K., Imprialos K. P., & Doumas M. (2017).  Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters.. JAMA Intern Med. 177(9), 1393.
2016
Boutari, C., Stavropoulos K., Imprialos K. P., Petidis K., & Doumas M. (2016).  Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?. Am J Hypertens. 29(5), 662.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.